Edwards Lifesciences CORP Form 4 insider transactions

Daniel J. Lippis, CVP, TAVR of Edwards Lifesciences Corp, sold 619 shares of common stock on August 11, 2026 for $92.03 per share.

Wayne Markowitz, CVP, JAPAC of Edwards Lifesciences Corp, sold 146 shares of common stock on July 30, 2026 for $86.03 per share.

Wayne Markowitz, CVP, JAPAC of Edwards Lifesciences Corp, sold 9,628 shares of common stock on July 28, 2026 for $85.06 per share.

Bernard J Zovighian, CEO and a Director of Edwards Lifesciences Corp, sold 2,921 shares of common stock on July 27, 2026 for $83.93 per share.

Annette Bruls, CVP, EMEACLA of Edwards Lifesciences Corp, reported a transaction in 109 shares of common stock on July 11, 2026.

Edwards Lifesciences Corp. reports on equity grants and option awards to Chief Financial Officer Theodora Mistras.

Daniel J. Lippis of Edwards Lifesciences Corp. reported transactions involving common stock and employee stock options on July 10, 2026, executed under a Rule 10b5-1 trading plan.

Daniel J. Lippis, a Corporate Vice President at Edwards Lifesciences Corp, reported a transaction involving the withholding of shares to cover tax obligations.

Daniel J. Lippis, a Corporate Vice President at Edwards Lifesciences Corp, executed a Rule 10b5-1 trading plan involving the acquisition and disposition of company stock.

CEO Bernard J. Zovighian sold 523 shares of Edwards Lifesciences common stock via a pre-arranged Rule 10b5-1 trading plan.

Andrew M. Dahl, SVP and Corporate Controller of Edwards Lifesciences, sold 567.5266 shares of common stock.

Donald E. Bobo Jr., CVP of Strategy and Corporate Development at Edwards Lifesciences, sold 23,145 shares of common stock.

Daveen Chopra, CVP of TMTT & Surgical at Edwards Lifesciences, sold 1,500 shares of common stock on May 22, 2026.

Daniel J. Lippis, CVP of TAVR at Edwards Lifesciences, exercised and sold 620 shares under a pre-arranged 10b5-1 trading plan.

Donald E. Bobo Jr., CVP of Strategy and Corporate Development at Edwards Lifesciences, reported the sale of 9,968 shares of common stock.

Edwards Lifesciences CEO Bernard J. Zovighian reported transactions involving the sale of company stock under a pre-arranged trading plan.

Donald E. Bobo Jr., VP of Strategy and Corporate Development at Edwards Lifesciences, reported transactions involving common stock and performance rights.

Daveen Chopra, CVP at Edwards Lifesciences Corp, reported a transaction involving the acquisition of performance rights and common stock.

CFO Scott Ullem acquired 19,830 shares through performance-based vesting, achieving 167.70% of target goals.

Wayne Markowitz, Corporate Vice President at Edwards Lifesciences, received significant equity awards including stock options and performance rights while selling a portion of existing holdings.

CEO Bernard J. Zovighian was awarded over 330,000 stock-based incentives, including options and performance rights, as part of a long-term compensation strategy.

Daniel J. Lippis, CVP of TAVR at Edwards Lifesciences, disposed of 362 shares to cover tax obligations on May 11, 2026.

Edwards Lifesciences Director Nicholas J. Valeriani was granted 5,127 restricted stock units as part of the company's nonemployee director incentive program.

Director Ramona Sequeira was granted 3,251 restricted stock units as part of the Edwards Lifesciences 2020 Nonemployee Directors Stock Incentive Program.

Director Steven R. Loranger acquired 4,315 restricted stock units in Edwards Lifesciences Corporation as part of the company's nonemployee director incentive program.

Director Paul A. LaViolette was granted 3,251 restricted stock units as part of the Edwards Lifesciences 2020 Nonemployee Directors Stock Incentive Program.

Edwards Lifesciences Director Leslie Stone Heisz was granted 3,251 restricted stock units as part of the company's nonemployee director incentive program.

Director Kieran Gallahue acquired 4,315 shares of Edwards Lifesciences common stock through restricted stock unit and award grants.

Director David T. Feinberg was granted 3,251 restricted stock units under the Edwards Lifesciences 2020 Nonemployee Directors Stock Incentive Program.

Donald E. Bobo Jr., CVP of Strategy/Corp Development at Edwards Lifesciences, reported new equity grants and tax-related share dispositions.